[Effectiveness of Leukostim, a Russian preparation of granulocyte colony-stimulating factor, in the treatment of chemotherapy-induced neutropenia in patients with malignant tumors].

Recombinant preparation of human G-CSF-Leukostim (Russia)--(filgrastim; analog of Neupogen)--was administered in 31 patients (breast cancer--28; ovarian carcinoma--3) to treat or prevent chemotherapy-induced neutropenia. The latter was aborted after 2-6 injections. Due to use of Leukostim, another course of chemotherapy (10 cycles) was successfully used in 5 breast cancer patients: no inhibition of hemopoiesis followed although the patients had suffered acute and persistent neutropenia from previous chemotherapy.

[Results of a phase I-II clinical trial of Emoxyl, a novel antineoplastic anthracycline].

Emoxyl (ruboxyl) is a product of chemical modification of daunorubicin mediated by a stable free radical. The drug was given to 63 patients with different malignancies stages I-II. Inhibition of hemopoiesis (leukopenia and thrombocytopenia) was identified as the dose-limiting toxicity level.